Lactobacillus reuteri (American Type Culture Collection Strain 55730) Versus Simethicone in the Treatment of Infantile Colic: A Prospective Randomized Study

  title={Lactobacillus reuteri (American Type Culture Collection Strain 55730) Versus Simethicone in the Treatment of Infantile Colic: A Prospective Randomized Study},
  author={Francesco Savino and E. Pelle and Elisabetta Palumeri and Roberto Oggero and Roberto Miniero},
  pages={e124 - e130}
OBJECTIVE The goal was to test the hypothesis that oral administration of Lactobacillus reuteri in a prospective randomized study would improve symptoms of infantile colic. [] Key MethodMETHODS Ninety breastfed colicky infants were assigned randomly to receive either the probiotic L. reuteri (10(8) live bacteria per day) or simethicone (60 mg/day) each day for 28 days. The mothers avoided cow's milk in their diet. Parents monitored daily crying times and adverse effects by using a questionnaire.

Figures and Tables from this paper

Lactobacillus reuteri DSM 17938 in Infantile Colic: A Randomized, Double-Blind, Placebo-Controlled Trial

L. reuteri DSM 17 938 at a dose of 108 colony-forming units per day in early breastfed infants improved symptoms of infantile colic and was well tolerated and safe.

Role of Lactobacillus rhamnosus (FloraActive™) 19070-2 and Lactobacillus reuteri (FloraActive™) 12246 in Infant Colic: A Randomized Dietary Study

It is confirmed that lactobacilli decrease cry and fuss time and provide a dietary support in exclusively breastfed infants with colic.

Lactobacillus rhamnosus GG (ATCC 53103) for the Management of Infantile Colic: A Randomized Controlled Trial

Infants treated with L. rhamnosus for 28 days, in association with the elimination of cow’s milk from the maternal diet, presented some interesting features related to the effect of this probiotic treatment: reductions in crying time and faecal calprotectin, with increased total bacteria and Lactobacillus.

Preventive effects of oral probiotic on infantile colic: a prospective, randomised, blinded, controlled trial using Lactobacillus reuteri DSM 17938.

The consumption of this probiotic is associated with a reduction of paediatric consultations for infantile colic, as well as use of pain relieving agents and of infant formula, and could reduce parental discomfort due to infantile Colic.

Probiotics to improve outcomes of colic in the community: Protocol for the Baby Biotics randomised controlled trial

The Baby Biotics trial aims to determine whether the probiotic Lactobacillus reuteri DSM 17938 is effective in reducing crying in infants less than three months old with infant colic when compared to placebo.

The effect of symbiotic in the treatment of infantile colic: A double-blind, randomized, placebo-controlled clinical trial

The authors did not find a significant improvement in colic symptoms in infants receiving symbiotic compared to placebo, and sleep duration in both the control and intervention groups increased.


Absence of LB acidophilus in colicky infants may predispose growth of other bacteria which may play a role in the pathogenesis of colic and its symptoms.

Growth and Tolerance of Term Infants Fed Formula With Probiotic Lactobacillus reuteri

Overall, between groups, there were no significant differences in formula intake, stool frequency, color, consistency, flatulence, frequency of spit-up/vomiting, mood, sleep, or incidence of adverse events.

Treating infant colic with the probiotic Lactobacillus reuteri: double blind, placebo controlled randomised trial

L reuteri DSM 17938 did not benefit a community sample of breastfed infants and formula fed infants with colic and do not support a general recommendation for the use of probiotics to treat colic.



Bacteriotherapy with Lactobacillus reuteri in rotavirus gastroenteritis.

L. reuteri effectively colonized the gastrointestinal tract after administration and significantly shortened the duration of watery diarrhea associated with rotavirus.

Effect of a Probiotic Infant Formula on Infections in Child Care Centers: Comparison of Two Probiotic Agents

Child care infants fed a formula supplemented with L reuteri or B lactis had fewer and shorter episodes of diarrhea, with no effect on respiratory illnesses, and were also the only supplement to improve additional morbidity parameters.

Bacterial counts of intestinal Lactobacillus species in infants with colic

  • F. SavinoE. Bailo L. Silvestro
  • Medicine
    Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology
  • 2005
Different colonization patterns of lactobacilli were found among colicky and healthy infants, suggesting how the observed differences may be involved in the pathogenesis of infantile colic increasing meteorism and abdominal distension.

Infantile colic: crying time reduction with a whey hydrolysate: A double-blind, randomized, placebo-controlled trial.

An extensively hydrolyzed whey formula is effective in reducing the duration of crying in a primary care setting and according to the intention to treat principle showed a difference in the decrease of crying duration.

Intestinal Microflora in Colicky and Noncolicky Infants: Bacterial Cultures and Gas‐Liquid Chromatography

No difference in intestinal microflora was found between the colicky infants at the time of colic and the controls, however, a difference in bacterial cellular fatty-acid profiles at the age of 3 months was found that correlated with severe infantile colic.

Effect of probiotic Lactobacillus strains in children with atopic dermatitis.

A combination of L rhamnosus 19070-2 and L reuteri DSM 122460 was beneficial in the management of AD, and the effect was more pronounced in patients with a positive skin prick test response and increased IgE levels.

Effect of a Low-Allergen Maternal Diet on Colic Among Breastfed Infants: A Randomized, Controlled Trial

Exclusion of allergenic foods from the maternal diet was associated with a reduction in distressed behavior among breastfed infants with colic presenting in the first 6 weeks of life.

Allergy development and the intestinal microflora during the first year of life.

Differences in the composition of the gut flora between infant who will and infants who will not develop allergy are demonstrable before the development of any clinical manifestations of atopy.